LMNL:CA:TSX-Liminal BioSciences Inc (CAD)

COMMON STOCK | Biotechnology | TSX

Last Closing Price

CAD 22.84

Change

0.00 (0.00)%

Market Cap

CAD 0.54B

Volume

0.03M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel treatments for patients suffering from diseases that have unmet medical needs. It operates through two segments, Small Molecule Therapeutics and Plasma Derived Therapeutics. The Small Molecule Therapeutics segment's lead product candidate is fezagepras (PBI-4050) for the treatment of idiopathic pulmonary fibrosis, respiratory diseases, and Alström Syndrome. The Plasma Derived Therapeutics segment provides Plasma Protein Purification System, a multi-product sequential purification process for the extraction and purification of therapeutic proteins from human plasma. It also engages in developing Ryplazim for the treatment of congenital plasminogen deficiency. The company operates in Canada, the United Kingdom, and the United States. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada. Address: 440 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4B4

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-02-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AUP:CA Aurinia Pharmaceuticals Inc

+0.23 (+1.27%)

CAD2.30B N/A N/A
TRIL:CA Trillium Therapeutics Inc

-0.97 (-6.30%)

CAD1.55B 1.80 N/A
APS:CA Aptose Biosciences Inc

-0.14 (-2.69%)

CAD0.46B N/A N/A
BLU:CA BELLUS Health Inc

+0.01 (+0.20%)

CAD0.39B N/A N/A
IMV:CA IMV Inc

-0.20 (-4.49%)

CAD0.30B -99,999.99 N/A
MDNA:CA Medicenna Therapeutics Corp

-0.07 (-1.35%)

CAD0.28B 5.40 N/A
FRX:CA Fennec Pharmaceuticals Inc

-0.61 (-5.94%)

CAD0.27B 30.20 N/A
RVX:CA Resverlogix Corp

-0.04 (-3.92%)

CAD0.24B 56.67 27.58
ATE:CA Antibe Therapeutics Inc

-0.41 (-7.55%)

CAD0.21B N/A N/A
ONC:CA Oncolytics Biotech Inc

-0.49 (-10.10%)

CAD0.21B N/A N/A

ETFs Containing LMNL:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.54B 89% B+ 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.28 88% B+ 96% A
Price/Book Ratio 6.87 63% D 15% F
Price / Cash Flow Ratio -5.43 22% F 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -130.97% 39% F 2% F
Return on Assets -42.40% 50% F 3% F
Debt to Equity Ratio 8.48% 100% A+ 84% B
Technical Ratios  
Short Ratio 3.64 17% F 23% F
Short Percent 3.80% 17% F 86% B
Beta 1.81 38% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.